-
1
-
-
28844480321
-
Management of hepatocellular carcinoma
-
Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
-
(2005)
Hepatology
, vol.42
, pp. 1208-1236
-
-
Bruix, J.1
Sherman, M.2
-
2
-
-
0033638414
-
Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring
-
Dufour D.R., Lott J.A., Nolte F.S., Gretch D.R., Koff R.S., Seeff L.B. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem 2000, 46:2050-2068.
-
(2000)
Clin Chem
, vol.46
, pp. 2050-2068
-
-
Dufour, D.R.1
Lott, J.A.2
Nolte, F.S.3
Gretch, D.R.4
Koff, R.S.5
Seeff, L.B.6
-
4
-
-
0037407560
-
Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults
-
Ryder S.D. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 2003, 52:1-8.
-
(2003)
Gut
, vol.52
, pp. 1-8
-
-
Ryder, S.D.1
-
5
-
-
77954314841
-
-
National Academy of clinical biochemistry guidelines for the use of tumor markers in primary liver cancer.
-
Lamerz R, Hayes P, Hoffmann RT, Löhe F, Shiratori Y, Taketa K. National Academy of clinical biochemistry guidelines for the use of tumor markers in primary liver cancer 2003, http://www.nacb.org/lmpg/tumor/chp3d_liver.pdf.
-
(2003)
-
-
Lamerz, R.1
Hayes, P.2
Hoffmann, R.T.3
Löhe, F.4
Shiratori, Y.5
Taketa, K.6
-
6
-
-
0027243462
-
Risk factors for hepatocellular carcinoma among patients with chronic liver disease
-
Tsukuma H., Hiyama T., Tanaka S., Nakao M., Yabuuchi T., Kitamura T., et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993, 328:1797-1801.
-
(1993)
N Engl J Med
, vol.328
, pp. 1797-1801
-
-
Tsukuma, H.1
Hiyama, T.2
Tanaka, S.3
Nakao, M.4
Yabuuchi, T.5
Kitamura, T.6
-
7
-
-
34548488009
-
AFP-L3 in chronic liver diseases with persistent elevation of alpha-fetoprotein
-
Cheng H.T., Chang Y.H., Chen Y.Y., Lee T.H., Tai D.I., Lin D.Y. AFP-L3 in chronic liver diseases with persistent elevation of alpha-fetoprotein. J Chin Med Assoc 2007, 70:310-317.
-
(2007)
J Chin Med Assoc
, vol.70
, pp. 310-317
-
-
Cheng, H.T.1
Chang, Y.H.2
Chen, Y.Y.3
Lee, T.H.4
Tai, D.I.5
Lin, D.Y.6
-
8
-
-
49849106705
-
Glycomic analysis of alpha-fetoprotein L3 in hepatoma cell lines and hepatocellular carcinoma patients
-
Nakagawa T., Miyoshi E., Yakushijin T., Hiramatsu N., Igura T., Hayashi N., et al. Glycomic analysis of alpha-fetoprotein L3 in hepatoma cell lines and hepatocellular carcinoma patients. J Proteome Res 2008, 7:2222-2233.
-
(2008)
J Proteome Res
, vol.7
, pp. 2222-2233
-
-
Nakagawa, T.1
Miyoshi, E.2
Yakushijin, T.3
Hiramatsu, N.4
Igura, T.5
Hayashi, N.6
-
9
-
-
30644467109
-
Usefulness of serum des-γ-carboxy prothrombin in detection of hepatocellular carcinoma
-
Wang C.S., Lin C.L., Lee H.C., Chen K.Y., Chiang M.F., Chen H.S., et al. Usefulness of serum des-γ-carboxy prothrombin in detection of hepatocellular carcinoma. World J Gastroenterol 2005, 11:6115-6119.
-
(2005)
World J Gastroenterol
, vol.11
, pp. 6115-6119
-
-
Wang, C.S.1
Lin, C.L.2
Lee, H.C.3
Chen, K.Y.4
Chiang, M.F.5
Chen, H.S.6
-
10
-
-
61749103943
-
The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma
-
Tommaso L.D., Destro A., Seok J.Y., Balladore E., Terracciano L., Sangiovanni A., et al. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol 2009, 50:746-754.
-
(2009)
J Hepatol
, vol.50
, pp. 746-754
-
-
Tommaso, L.D.1
Destro, A.2
Seok, J.Y.3
Balladore, E.4
Terracciano, L.5
Sangiovanni, A.6
-
11
-
-
59849114315
-
Cancers of the pancreas and hepatobiliary system
-
Sauerland C., Engelking C., Wickham R., Pearlstone D.B. Cancers of the pancreas and hepatobiliary system. Semin Oncol Nurs 2009, 25:76-92.
-
(2009)
Semin Oncol Nurs
, vol.25
, pp. 76-92
-
-
Sauerland, C.1
Engelking, C.2
Wickham, R.3
Pearlstone, D.B.4
-
12
-
-
62849103665
-
Significance of serum tumor markers carcinoembryonic antigen, CA19-9, CA 125, and CA 15-3 in pre-orthotopic liver transplantation evaluation
-
Pissaia A., Bernard J.D., Scatton O., Soubrane O., Conti F., Calmus Y. Significance of serum tumor markers carcinoembryonic antigen, CA19-9, CA 125, and CA 15-3 in pre-orthotopic liver transplantation evaluation. Transplant Proc 2009, 41:682-684.
-
(2009)
Transplant Proc
, vol.41
, pp. 682-684
-
-
Pissaia, A.1
Bernard, J.D.2
Scatton, O.3
Soubrane, O.4
Conti, F.5
Calmus, Y.6
-
13
-
-
0344069531
-
Differential tumor markers and hepatitis markers profile in liver tumors
-
Khalifa A., Mady E.A., Abadeer N., Kamal A. Differential tumor markers and hepatitis markers profile in liver tumors. Anticancer Res 1999, 19:2495-2500.
-
(1999)
Anticancer Res
, vol.19
, pp. 2495-2500
-
-
Khalifa, A.1
Mady, E.A.2
Abadeer, N.3
Kamal, A.4
-
14
-
-
0026877124
-
Hepatocellular carcinoma producing carcinoembryonic antigen and carbohydrate antigen 19-9
-
Usui Y., Miura H., Kimura Y., Takayama S., Nakayama M. Hepatocellular carcinoma producing carcinoembryonic antigen and carbohydrate antigen 19-9. Intern Med 1992, 31:791-793.
-
(1992)
Intern Med
, vol.31
, pp. 791-793
-
-
Usui, Y.1
Miura, H.2
Kimura, Y.3
Takayama, S.4
Nakayama, M.5
-
15
-
-
0034893110
-
Glypicans: proteoglycans with a surprise
-
Filmus J., Selleck S.B. Glypicans: proteoglycans with a surprise. J Clin Invest 2001, 108:497-501.
-
(2001)
J Clin Invest
, vol.108
, pp. 497-501
-
-
Filmus, J.1
Selleck, S.B.2
-
16
-
-
5144233509
-
Identification of glypican-3 as a novel tumor marker for melanoma
-
Tetsuya N., Toshiro K., Shosuke I., Kazumasa W., Mikio M., Yoshiaki I., et al. Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res 2004, 10:6612-6621.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 6612-6621
-
-
Tetsuya, N.1
Toshiro, K.2
Shosuke, I.3
Kazumasa, W.4
Mikio, M.5
Yoshiaki, I.6
-
17
-
-
77954314730
-
-
Methods for diagnosing and treating prostate cancer, US Patent 20070154964.
-
Wang B, Wab M. Methods for diagnosing and treating prostate cancer, US Patent 20070154964.
-
-
-
Wang, B.1
Wab, M.2
-
18
-
-
0038752042
-
Glypican-3 is overexpressed in human hepatocellular carcinoma
-
Sung Y.K., Hwang S.Y., Park M.K., Farooq M., Han I.S., Bae H.I., et al. Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Sci 2003, 94:259-262.
-
(2003)
Cancer Sci
, vol.94
, pp. 259-262
-
-
Sung, Y.K.1
Hwang, S.Y.2
Park, M.K.3
Farooq, M.4
Han, I.S.5
Bae, H.I.6
-
19
-
-
0038786861
-
Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma
-
Capurro M., Wanless I.R., Sherman M., Deboer G., Shi W., Miyoshi E. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003, 125:89-97.
-
(2003)
Gastroenterology
, vol.125
, pp. 89-97
-
-
Capurro, M.1
Wanless, I.R.2
Sherman, M.3
Deboer, G.4
Shi, W.5
Miyoshi, E.6
-
20
-
-
0038054270
-
Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker
-
Tetsuya N., Yoshihiro Y., Satoru S., Mikio M., Hiroyuki K., Yutaka M., et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003, 306:16-25.
-
(2003)
Biochem Biophys Res Commun
, vol.306
, pp. 16-25
-
-
Tetsuya, N.1
Yoshihiro, Y.2
Satoru, S.3
Mikio, M.4
Hiroyuki, K.5
Yutaka, M.6
-
21
-
-
0035086268
-
Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders
-
Zhu Z.W., Friess H., Wang L., Abou-Shady M., Zimmermann A., Lander A.D., et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 2001, 48:558-564.
-
(2001)
Gut
, vol.48
, pp. 558-564
-
-
Zhu, Z.W.1
Friess, H.2
Wang, L.3
Abou-Shady, M.4
Zimmermann, A.5
Lander, A.D.6
-
22
-
-
27944433471
-
The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma
-
Yamauchi N., Watanabe A., Hishinuma M., Ohashi K.I., Midorikawa Y., Morishita Y., et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 2005, 18:1591-1598.
-
(2005)
Mod Pathol
, vol.18
, pp. 1591-1598
-
-
Yamauchi, N.1
Watanabe, A.2
Hishinuma, M.3
Ohashi, K.I.4
Midorikawa, Y.5
Morishita, Y.6
-
23
-
-
0034688147
-
Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma
-
Murthy S.S., Shen T., De Rienzo A., Lee W.C., Ferriola P.C., Jhanwar S.C., et al. Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene 2000, 19:410-416.
-
(2000)
Oncogene
, vol.19
, pp. 410-416
-
-
Murthy, S.S.1
Shen, T.2
De Rienzo, A.3
Lee, W.C.4
Ferriola, P.C.5
Jhanwar, S.C.6
-
24
-
-
0035504922
-
Glypican-3 expression is silenced in human breast cancer
-
Xiang Y.Y., Ladeda V., Filmus J. Glypican-3 expression is silenced in human breast cancer. Oncogene 2001, 20:7408-7412.
-
(2001)
Oncogene
, vol.20
, pp. 7408-7412
-
-
Xiang, Y.Y.1
Ladeda, V.2
Filmus, J.3
-
25
-
-
9144257933
-
The heparan sulfate proteoglycan GPC3 is a potential lung tumor suppressor
-
Kim H., Xu G.L., Borczuk A.C., Busch S., Filmus J., Capurro M., et al. The heparan sulfate proteoglycan GPC3 is a potential lung tumor suppressor. Am J Respir Cell Mol Biol 2003, 29:694-701.
-
(2003)
Am J Respir Cell Mol Biol
, vol.29
, pp. 694-701
-
-
Kim, H.1
Xu, G.L.2
Borczuk, A.C.3
Busch, S.4
Filmus, J.5
Capurro, M.6
-
26
-
-
0036064793
-
Glypican-3 expression is markedly decreased in human gastric cancer but not in esophageal cancer
-
Zhu Z., Friess H., Kleeff J., Wang L., Wirtz M., Zimmermann A., et al. Glypican-3 expression is markedly decreased in human gastric cancer but not in esophageal cancer. Am J Surg 2002, 184:78-83.
-
(2002)
Am J Surg
, vol.184
, pp. 78-83
-
-
Zhu, Z.1
Friess, H.2
Kleeff, J.3
Wang, L.4
Wirtz, M.5
Zimmermann, A.6
-
27
-
-
0033557918
-
Frequent silencing of the GPC3 gene in ovarian cancer cell lines
-
Lin H., Huber R., Schlessinger D., Morin P.J. Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res 1999, 59:807-810.
-
(1999)
Cancer Res
, vol.59
, pp. 807-810
-
-
Lin, H.1
Huber, R.2
Schlessinger, D.3
Morin, P.J.4
-
28
-
-
13344261391
-
Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome
-
Pilia G., Hughes-Benzie R.M., MacKenzie A., Baybayan P., Chen E.Y., Huber R., et al. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nature Genetics 1996, 12:241-247.
-
(1996)
Nature Genetics
, vol.12
, pp. 241-247
-
-
Pilia, G.1
Hughes-Benzie, R.M.2
MacKenzie, A.3
Baybayan, P.4
Chen, E.Y.5
Huber, R.6
-
30
-
-
11244326977
-
Glypican-3 as a serum marker for hepatocellular carcinoma
-
Capurro M., Filmus J. Glypican-3 as a serum marker for hepatocellular carcinoma. Cancer Res 2005, 65:372-373.
-
(2005)
Cancer Res
, vol.65
, pp. 372-373
-
-
Capurro, M.1
Filmus, J.2
-
31
-
-
27244454806
-
Mechanisms of heat-induced antigen retrieval: does pH or ionic strength of the solution play a role for refolding antigens
-
Emoto K., Yamashita S., Okada Y. Mechanisms of heat-induced antigen retrieval: does pH or ionic strength of the solution play a role for refolding antigens. J Histochem Cytochem 2005, 53:1311-1321.
-
(2005)
J Histochem Cytochem
, vol.53
, pp. 1311-1321
-
-
Emoto, K.1
Yamashita, S.2
Okada, Y.3
-
32
-
-
0028204881
-
Noncompetitive immunoassay of thyroxine using a liquid-phase binding assay
-
Hara T., Nakamura K., Satomura S., Matsuura S. Noncompetitive immunoassay of thyroxine using a liquid-phase binding assay. Anal Chem 1994, 66:351-354.
-
(1994)
Anal Chem
, vol.66
, pp. 351-354
-
-
Hara, T.1
Nakamura, K.2
Satomura, S.3
Matsuura, S.4
-
33
-
-
33947396135
-
Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis
-
Tommaso L.D., Franchi G., Park Y.N., Fiamengo B., Destro A., Morenghi E., et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 2007, 45:725-734.
-
(2007)
Hepatology
, vol.45
, pp. 725-734
-
-
Tommaso, L.D.1
Franchi, G.2
Park, Y.N.3
Fiamengo, B.4
Destro, A.5
Morenghi, E.6
|